Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Cardiovasc Drugs Ther ; 25(3): 243-50, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21584633

ABSTRACT

PURPOSE: The objective of our study was to identify changes in the coagulation and serum concentration of soluble P-selectin (sP-sel) after i.v. bolus of 0.75 mg/kg enoxaparin in a group of 33 patients during PCI. METHODS AND RESULTS: As compared to baseline, i.v. enoxaparin increased anti -Xa activity and FIIa inhibition together with APTT and thrombin time tests within 20 min, that persisted for 60 min. At 6 h, the results of all tests had returned to baseline. In contrast, the level of prothrombin fragments (F1 + 2) decreased persistingly for a period of 6 h (baseline 1.19 ± 0.42 nmol/l, after 20 min 1.03 ± 0.46 nmol/l, after 60 min 1.06 ± 0.43 nmol/l, after 6 h 0.95 ± 0.40 nmol/l, p < 0.001 vs. baseline for all values). In addition, i.v. enoxaparin decreased serum sP-sel level (baseline 111.80 ± 37.05 ng/ml, after 20 min 87.80 ± 33.17 ng/ml, after 60 min 86.45 ± 29.15 ng/ml, after 6 h 92.24 ± 31.34 ng/ml, p < 0.001 vs. baseline value for all). sP-sel level mildly correlated with both F Xa inhibition (r = -0.275, p < 0.05) and F1 + 2 level (r = 0.274, p < 0.05). CONCLUSION: Intravenous enoxaparin induced target F Xa inhibition (>0.6 IU/ml) for 60 min in 82% of study patients. During the 6 h of monitoring, a decrease of thrombin generation (F1 + 2) and sP-selectin levels were observed.


Subject(s)
Angioplasty, Balloon, Coronary/methods , Enoxaparin/pharmacology , P-Selectin/drug effects , Thrombin/drug effects , Aged , Aged, 80 and over , Anticoagulants/pharmacology , Coronary Artery Disease/therapy , Factor Xa Inhibitors , Female , Humans , Injections, Intravenous , Male , Middle Aged , P-Selectin/metabolism , Partial Thromboplastin Time , Prothrombin/antagonists & inhibitors , Thrombin/metabolism , Thrombin Time , Time Factors
2.
Cas Lek Cesk ; 146(7): 597-602, 2007.
Article in Czech | MEDLINE | ID: mdl-17722847

ABSTRACT

Patients with severe sepsis are at increased risk for developing thrombembolic phenomena. This article aims to clarify the association between systemic inflammation activation and coagulation, pathogenesis of coagulation abnormalities during severe sepsis. The article reviews incidence and deep venous thrombosis risk factors among these patients and summarizes recent evidence-based guidelines for deep venous thrombosis prophylaxis.


Subject(s)
Pulmonary Embolism/etiology , Sepsis/complications , Venous Thrombosis/etiology , Blood Coagulation , Humans , Pulmonary Embolism/prevention & control , Sepsis/blood , Venous Thrombosis/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...